Condition
GVHD,Acute clinical trials and research
As of November 12, 2026, Find a Trial lists 4 GVHD,Acute clinical trials that are recruiting, at sites in 2 countries (most in United States (3), China (1)). By phase: Phase 2 (2), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest GVHD,Acute clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| First-line ruxolitinib plus corticosteroids for grade II acute graft-versus-host disease | Phase 2 | Beijing, Beijing Municipality | Recruiting | Jan 14, 2026 |
| Preventing GvHD in patients with blood cancers undergoing stem cell transplants | Phase 1 | Duarte, California and 4 other locations | Recruiting | Jun 17, 2024 |
| Two-step ATG to prevent GVHD after myeloablative allogeneic stem cell transplant | Phase 2 | Birmingham, Alabama | Recruiting | Mar 18, 2024 |
| Predicting acute graft versus host disease using blood samples | — | Detroit, Michigan | Recruiting | Feb 8, 2023 |
All recruiting trials (4)
-
First-line ruxolitinib plus corticosteroids for grade II acute graft-versus-host disease
This trial will test whether adding ruxolitinib to standard corticosteroids helps people with new grade II acute graft-versus-host disease after an allogeneic stem cell transplant.
-
Preventing GvHD in patients with blood cancers undergoing stem cell transplants
This study is testing a new treatment called TRX-103 to see if it can help prevent graft-versus-host disease in people with blood cancers who are getting stem cell transplants from mismatched donors.
-
Two-step ATG to prevent GVHD after myeloablative allogeneic stem cell transplant
This study tests whether a two-step dosing of rabbit ATG added to tacrolimus and low-dose methotrexate can help prevent severe acute and chronic GVHD in adults 18–60 receiving myeloablative allogeneic peripheral blood stem cell transplants for leukemia, MDS, or myeloproliferative disorders.
-
Predicting acute graft versus host disease using blood samples
This study is trying to find specific markers in blood samples that can help predict if patients over 18 will develop severe acute graft versus host disease after receiving a stem cell transplant.
Related topics
Quick answers
How many GVHD,Acute clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (3 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.